ArticleJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2012
A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery.
Article in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- Dual-enzyme activated theranostic nanoparticles for image-guided glioblastoma therapy.Scientific reports · 2025Article
- Machine learning assisted-nanomedicine using magnetic nanoparticles for central nervous system diseases.Nanoscale advances · 2023Review
- Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II).Brain sciences · 2021Review
- Imaging Characteristics of USPIO Nanoparticles (<5 nm) as MR Contrast AgentContrast media & molecular imaging · 2019Article
- Magnetic micelles for DNA delivery to rat brains after mild traumatic brain injury.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Monitoring adenoviral based gene delivery in rat glioma by molecular imaging.World journal of clinical oncology · 2013Article
- Strategies in gene therapy for glioblastoma.Cancers · 2013Article
- Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use.Stem cells translational medicine · 2013Article
- Progress in gene therapy for neurological disorders.Nature reviews. Neurology · 2013Review
- Nanoparticles based stem cell tracking in regenerative medicine.Theranostics · 2013Review
- Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience.Journal of drug delivery · 2013Article
- Anti-angiogenic gene therapy in the treatment of malignant gliomas.Neuroscience letters · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
In vivo tracking of gene therapy vectors challenges the investigation and improvement of biodistribution of these agents in the brain, a key feature for their targeting of infiltrative malignant gliomas. The glioma-targeting Ad5/3-cRGD gene therapy vector was covalently bound to super-paramagnetic iron oxide (Fe(3)O(4)) nanoparticles (SPION) to monitor its distribution by MRI. Transduction of labeled and unlabeled vectors was assessed on the U87 glioma cell line and normal human astrocytes (NHA), and was higher in U87 compared to NHA, but was similar between labeled and unlabeled virus. An in vivo study was performed by intracranial subcortical injection of labeled-Ad5/3-cRGD particles into a pig brain. The labeled vector appeared in vivo as a T2-weighted hyperintensity and a T2-gradient echo signal at the injection site, persisting up to 72 hours post-injection. We describe a glioma-targeting vector that is labeled with SPION, thereby allowing for MRI detection with no change in transduction capability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.